Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials
| Autor: | Girish K. Srivastava, Irene Carretero-Barrio, Sara Alvarez-Sanchez, Jorge González-Zamora, Maria Luz Alonso-Alonso, Jose-Carlos Pastor, Ivan Fernandez-Bueno, Sonia Labrador-Velandia |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Pathology
medicine.medical_specialty Histology genetic structures Células madre Cell therapy Retina 03 medical and health sciences chemistry.chemical_compound Clinical trials 0302 clinical medicine Genetics medicine Molecular Biology Optic nerve diseases Genetics (clinical) business.industry Mesenchymal stem cell Minireviews Retinal Cell Biology Retinal diseases eye diseases Clinical trial medicine.anatomical_structure chemistry 030221 ophthalmology & optometry Mesenchymal stem cells sense organs business 030217 neurology & neurosurgery |
| Zdroj: | UVaDOC. Repositorio Documental de la Universidad de Valladolid instname World Journal of Stem Cells |
| Popis: | Producción Científica Retinal and optic nerve diseases are degenerative ocular pathologies which lead to irreversible visual loss. Since the advanced therapies availability, cell-based therapies offer a new all-encompassing approach. Advances in the knowledge of neuroprotection, immunomodulation and regenerative properties of mesenchymal stem cells (MSCs) have been obtained by several preclinical studies of various neurodegenerative diseases. It has provided the opportunity to perform the translation of this knowledge to prospective treatment approaches for clinical practice. Since 2008, several first steps projecting new treatment approaches, have been taken regarding the use of cell therapy in patients with neurodegenerative pathologies of optic nerve and retina. Most of the clinical trials using MSCs are in Ⅰ/Ⅱ phase, recruiting patients or ongoing, and they have as main objective the safety assessment of MSCs using various routes of administration. However, it is important to recognize that, there is still a long way to go to reach clinical trials phase Ⅲ-Ⅳ. Hence, it is necessary to continue preclinical and clinical studies to improve this new therapeutic tool. This paper reviews the latest progress of MSCs in human clinical trials for retinal and optic nerve diseases Junta de Castilla y León (programa de apoyo a proyectos de investigación – Ref. VA066U13) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|